• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

KDM6A-SND1 相互作用通过保护新生 DNA 来维持基因组稳定性,并有助于癌症的化疗耐药性。

KDM6A-SND1 interaction maintains genomic stability by protecting the nascent DNA and contributes to cancer chemoresistance.

机构信息

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Nucleic Acids Res. 2024 Jul 22;52(13):7665-7686. doi: 10.1093/nar/gkae487.

DOI:10.1093/nar/gkae487
PMID:38850159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11260493/
Abstract

Genomic instability is one of the hallmarks of cancer. While loss of histone demethylase KDM6A increases the risk of tumorigenesis, its specific role in maintaining genomic stability remains poorly understood. Here, we propose a mechanism in which KDM6A maintains genomic stability independently on its demethylase activity. This occurs through its interaction with SND1, resulting in the establishment of a protective chromatin state that prevents replication fork collapse by recruiting of RPA and Ku70 to nascent DNA strand. Notably, KDM6A-SND1 interaction is up-regulated by KDM6A SUMOylation, while KDM6AK90A mutation almost abolish the interaction. Loss of KDM6A or SND1 leads to increased enrichment of H3K9ac and H4K8ac but attenuates the enrichment of Ku70 and H3K4me3 at nascent DNA strand. This subsequently results in enhanced cellular sensitivity to genotoxins and genomic instability. Consistent with these findings, knockdown of KDM6A and SND1 in esophageal squamous cell carcinoma (ESCC) cells increases genotoxin sensitivity. Intriguingly, KDM6A H101D & P110S, N1156T and D1216N mutations identified in ESCC patients promote genotoxin resistance via increased SND1 association. Our finding provides novel insights into the pivotal role of KDM6A-SND1 in genomic stability and chemoresistance, implying that targeting KDM6A and/or its interaction with SND1 may be a promising strategy to overcome the chemoresistance.

摘要

基因组不稳定性是癌症的标志之一。虽然组蛋白去甲基酶 KDM6A 的丢失会增加肿瘤发生的风险,但它在维持基因组稳定性方面的具体作用仍知之甚少。在这里,我们提出了一种机制,即 KDM6A 通过与 SND1 的相互作用,独立于其去甲基酶活性来维持基因组稳定性。这种作用是通过其与 SND1 的相互作用来实现的,从而建立了一种保护染色质状态,通过招募 RPA 和 Ku70 到新生 DNA 链来防止复制叉崩溃。值得注意的是,KDM6A-SND1 相互作用受 KDM6A SUMOylation 的上调调节,而 KDM6AK90A 突变几乎消除了这种相互作用。KDM6A 或 SND1 的缺失导致 H3K9ac 和 H4K8ac 的富集增加,但削弱了新生 DNA 链上 Ku70 和 H3K4me3 的富集。这随后导致细胞对遗传毒物和基因组不稳定性的敏感性增加。与这些发现一致的是,在食管鳞状细胞癌(ESCC)细胞中敲低 KDM6A 和 SND1 增加了遗传毒物的敏感性。有趣的是,在 ESCC 患者中鉴定的 KDM6A H101D 和 P110S、N1156T 和 D1216N 突变通过增加 SND1 关联促进了遗传毒物抗性。我们的发现为 KDM6A-SND1 在基因组稳定性和化疗耐药性中的关键作用提供了新的见解,这表明靶向 KDM6A 和/或其与 SND1 的相互作用可能是克服化疗耐药性的一种有前途的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/bea47623ef37/gkae487fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/848758e0f559/gkae487figgra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/0708adaa20d1/gkae487fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/d84ff25fb340/gkae487fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/81cd9a861358/gkae487fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/801116629f13/gkae487fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/8280c27298dd/gkae487fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/0c280be3321e/gkae487fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/1c57dc16eac2/gkae487fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/a6f04b9ec648/gkae487fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/bea47623ef37/gkae487fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/848758e0f559/gkae487figgra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/0708adaa20d1/gkae487fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/d84ff25fb340/gkae487fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/81cd9a861358/gkae487fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/801116629f13/gkae487fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/8280c27298dd/gkae487fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/0c280be3321e/gkae487fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/1c57dc16eac2/gkae487fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/a6f04b9ec648/gkae487fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1262/11260493/bea47623ef37/gkae487fig9.jpg

相似文献

1
KDM6A-SND1 interaction maintains genomic stability by protecting the nascent DNA and contributes to cancer chemoresistance.KDM6A-SND1 相互作用通过保护新生 DNA 来维持基因组稳定性,并有助于癌症的化疗耐药性。
Nucleic Acids Res. 2024 Jul 22;52(13):7665-7686. doi: 10.1093/nar/gkae487.
2
Correction to 'KDM6A-SND1 interaction maintains genomic stability by protecting the nascent DNA and contributes to cancer chemoresistance'.对“KDM6A-SND1相互作用通过保护新生DNA维持基因组稳定性并促进癌症化疗耐药性”的修正
Nucleic Acids Res. 2024 Jul 22;52(13):8038. doi: 10.1093/nar/gkae581.
3
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.KDM6A 的缺失是人类胰腺癌预后不良的亚型特征,并增强了 HDAC 抑制剂的致死性。
Int J Cancer. 2019 Jul 1;145(1):192-205. doi: 10.1002/ijc.32072. Epub 2018 Dec 30.
4
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.癌症驱动基因异柠檬酸脱氢酶1/2(IDH1/2)、含Jumonji结构域的赖氨酸去甲基化酶1C/赖氨酸特异性去甲基化酶5C(JARID1C/KDM5C)以及含泛素羧基末端水解酶结构域的赖氨酸去甲基化酶6A/赖氨酸特异性去甲基化酶6A(UTX/KDM6A):癌症代谢中组蛋白去甲基化与缺氧重编程之间的相互作用
Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6.
5
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.组蛋白 3 赖氨酸-27 去甲基化酶 KDM6A 与 KMT2B 协调作用,通过调节 H3K4me3 在 NSCLC 中发挥致癌作用。
Oncogene. 2020 Oct;39(41):6468-6479. doi: 10.1038/s41388-020-01449-y. Epub 2020 Sep 2.
6
System Review about Function Role of ESCC Driver Gene KDM6A by Network Biology Approach.基于网络生物学方法对食管鳞状细胞癌驱动基因KDM6A功能作用的系统综述。
ScientificWorldJournal. 2016;2016:1970904. doi: 10.1155/2016/1970904. Epub 2016 May 17.
7
Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma.异常的 MCM10 SUMOylation 通过与食管鳞状细胞癌生存相关的遗传变异引起基因组不稳定性。
Clin Transl Med. 2021 Jun;11(6):e485. doi: 10.1002/ctm2.485.
8
KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress.子宫颈癌细胞系的KDM6A成瘾由E7触发,并由p21CIP1对复制应激的抑制介导。
PLoS Pathog. 2017 Oct 2;13(10):e1006661. doi: 10.1371/journal.ppat.1006661. eCollection 2017 Oct.
9
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate.组蛋白去甲基化酶 KDM6A 直接感知氧气以控制染色质和细胞命运。
Science. 2019 Mar 15;363(6432):1217-1222. doi: 10.1126/science.aaw1026. Epub 2019 Mar 14.
10
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.赖氨酸去甲基化酶 KDM6A 在分化、发育和癌症中的作用。
Mol Cell Biol. 2020 Sep 28;40(20). doi: 10.1128/MCB.00341-20.

引用本文的文献

1
Breaking the oncogenic alliance: advances in disrupting the MTDH-SND1 complex for cancer therapy.打破致癌联盟:破坏MTDH-SND1复合物用于癌症治疗的研究进展
RSC Adv. 2025 Aug 26;15(37):30165-30188. doi: 10.1039/d5ra04310g. eCollection 2025 Aug 22.
2
SREBF1-mediated SND1 transcriptional activation promotes prostate cancer progression via MTDH interaction through the SESN2/AMPK/mTOR axis.SREBF1介导的SND1转录激活通过SESN2/AMPK/mTOR轴与MTDH相互作用促进前列腺癌进展。
J Transl Med. 2025 Aug 7;23(1):885. doi: 10.1186/s12967-025-06762-2.
3
Staphylococcal nuclease and tudor domain-containing protein 1: An emerging therapeutic target in cancer (Review).

本文引用的文献

1
ATR limits Rad18-mediated PCNA monoubiquitination to preserve replication fork and telomerase-independent telomere stability.ATR 限制 Rad18 介导的 PCNA 单泛素化以维持复制叉和端粒酶独立的端粒稳定性。
EMBO J. 2024 Apr;43(7):1301-1324. doi: 10.1038/s44318-024-00066-9. Epub 2024 Mar 11.
2
Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy.靶向 CRL4 诱导自噬抑制耐药性卵巢癌细胞生长。
Signal Transduct Target Ther. 2022 Dec 9;7(1):388. doi: 10.1038/s41392-022-01253-y.
3
Signalling mechanisms and cellular functions of SUMO.
含葡萄球菌核酸酶和Tudor结构域蛋白1:癌症中一个新出现的治疗靶点(综述)
Mol Clin Oncol. 2025 Jul 17;23(4):86. doi: 10.3892/mco.2025.2881. eCollection 2025 Oct.
4
Genome-wide CRISPR/Cas9 screening identifies PTGR2 as a potential therapeutic target for sunitinib resistance in clear cell renal cell carcinoma.全基因组CRISPR/Cas9筛选确定PTGR2为透明细胞肾细胞癌中舒尼替尼耐药的潜在治疗靶点。
Sci Rep. 2025 Jul 19;15(1):26263. doi: 10.1038/s41598-025-12192-3.
5
EZH2 regulates tumor-associated macrophages by the KDM6A-mediated inflammatory response in HPV16-positive cervical cancer.EZH2通过KDM6A介导的炎症反应在HPV16阳性宫颈癌中调节肿瘤相关巨噬细胞。
Hum Cell. 2025 Jun 19;38(4):119. doi: 10.1007/s13577-025-01246-3.
6
PCYT2 inhibits epithelial-mesenchymal transition in colorectal cancer by elevating YAP1 phosphorylation.PCYT2通过提高YAP1磷酸化水平来抑制结直肠癌中的上皮-间质转化。
JCI Insight. 2024 Dec 20;9(24):e178823. doi: 10.1172/jci.insight.178823.
SUMO 的信号机制和细胞功能。
Nat Rev Mol Cell Biol. 2022 Nov;23(11):715-731. doi: 10.1038/s41580-022-00500-y. Epub 2022 Jun 24.
4
Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair.靶向DNA双链断裂修复的非PIKKs小分子抑制剂开发的最新进展
Front Oncol. 2022 Apr 6;12:850883. doi: 10.3389/fonc.2022.850883. eCollection 2022.
5
SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response.SND1 通过靶向 DNA 损伤反应促进宫颈癌耐药。
Cancer Biother Radiopharm. 2024 Aug;39(6):425-434. doi: 10.1089/cbr.2021.0371. Epub 2022 Mar 10.
6
METTL3-mediated mA mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.METTL3介导的m⁶A mRNA修饰通过Notch信号通路促进食管癌的发生和发展。
Mol Ther Nucleic Acids. 2021 Jul 21;26:333-346. doi: 10.1016/j.omtn.2021.07.007. eCollection 2021 Dec 3.
7
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.组蛋白 H3K27 去甲基化酶 KDM6A 是癌症中 mTORC1 信号的表观遗传守门员。
Gut. 2022 Aug;71(8):1613-1628. doi: 10.1136/gutjnl-2021-325405. Epub 2021 Sep 11.
8
The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy.食管鳞癌放化疗后不断演变的基因组图谱。
Cancer Res. 2021 Oct 1;81(19):4926-4938. doi: 10.1158/0008-5472.CAN-21-0653. Epub 2021 Aug 19.
9
KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.KDM5A 和 KDM5B 组蛋白去甲基化酶有助于 HU 诱导的复制应激反应和耐受。
Biol Open. 2021 May 15;10(5). doi: 10.1242/bio.057729. Epub 2021 May 26.
10
Rtt105 promotes high-fidelity DNA replication and repair by regulating the single-stranded DNA-binding factor RPA.Rtt105 通过调节单链 DNA 结合因子 RPA 促进高保真 DNA 复制和修复。
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25). doi: 10.1073/pnas.2106393118.